NuVasive Inc (NUVA)

54.70
0.45 0.83
NASDAQ : Health Care
Prev Close 54.25
Open 54.15
Day Low/High 54.00 / 54.34
52 Wk Low/High 36.81 / 62.95
Volume 24.35K
Avg Volume 1.17M
Exchange NASDAQ
Shares Outstanding 50.80M
Market Cap 2.77B
EPS 0.70
P/E Ratio 88.08
Div & Yield N.A. (N.A)

Latest News

NuVasive Announces Acquisition Of Vertera Spine

NuVasive Announces Acquisition Of Vertera Spine

NuVasive invests in advanced materials science portfolio with first-of-its-kind porous PEEK technology

NuVasive Receives FDA 510(k) Clearance For Leading EOS Innovation

NuVasive Receives FDA 510(k) Clearance For Leading EOS Innovation

Latest clearance unites RELINE­® Small Stature fixation portfolio with the MAGEC@ System and introduces a new design with 5.0 millimeter rod to be unveiled at Scoliosis Research Society 52nd Annual Meeting

NuVasive Announces World-Class Innovation Center At San Diego Headquarters

NuVasive Announces World-Class Innovation Center At San Diego Headquarters

The Company's plans include expansion of state-of-the-art surgeon education lab, creation of a new technology innovation center and extension of work space as talent base grows

InfoBionic Appoints Gene Cattarina To Board Of Directors

InfoBionic Appoints Gene Cattarina To Board Of Directors

Mr. Cattarina Brings 40+ Years of Leadership Experience in Healthcare IT and Medical Devices

NuVasive Appoints Rajesh J. Asarpota As Chief Financial Officer

NuVasive Appoints Rajesh J. Asarpota As Chief Financial Officer

Financial and operational veteran to support Company's continued growth strategy and profitability goals

Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

And a management shakeup helps push down NuVasive.

NuVasive Announces New Organizational Structure To Drive Growth And Profitability Goals

NuVasive Announces New Organizational Structure To Drive Growth And Profitability Goals

New structure designed to align strategy and innovation, integrate global commercial channels and transform business operations

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AIG, ALSK, GNE, GUID, HTH, LPI, NUVA, PIRS, QRVO, S, TTMI Downgrades: ARRS, BPMC, CONE, CRAY, EFII, GIL, GKOS, HYH, SUM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

NUVA: Insiders vs. Shorts

The most recent short interest data was recently released for the 04/13/2017 settlement date, and Nuvasive Inc is one of the most shorted stocks of the Russell 3000, based on 10.25 "days to cover" versus the median component at 5.14. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Insider Bets Paying Off At NUVA As New 52-Week High Reached

In trading on Monday, shares of Nuvasive Inc touched a new 52-week high of $77.88/share. That's a 56.17% rise, or $28.01 per share from the 52-week low of $49.87 set back on 04/22/2016.

NuVasive Receives First-Ever FDA Clearance For Cervical Interbody Implant System Used In More Than Two Levels

FDA 510(k) Clearance for CoRoent® Small Interbody™ System Includes Indication for Treatment of Cervical Disc Degeneration at up to Four Contiguous Levels

New Evidence-Based Recommendation Released From NICE (U.K.) For Lateral Interbody Fusion

NICE Guidance Supported by Literature Review of More than 200 Peer-Reviewed Articles Primarily Reflecting Experience with NuVasive's Industry-Leading XLIF Procedure

Masimo's Stock Is a Great Buy Right Now

Masimo's Stock Is a Great Buy Right Now

This patient-monitoring device-maker has plenty of room for growth.

NUVA: Insiders vs. Shorts

The most recent short interest data was recently released for the 01/13/2017 settlement date, and Nuvasive Inc is one of the most shorted stocks of the Russell 3000, based on 6.67 "days to cover" versus the median component at 5.04. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Are People Finally Noticing?

Recognition of the market's inertia seems to be growing.

TheStreet Quant Rating: B- (Buy)